Plant Name: Brassica oleracea var. sabauda
Taxonomic Information:
Plant ID: NPO7576.2
Plant Latin Name: Brassica oleracea var. sabauda
Taxonomy Genus: Brassica
Taxonomy Family: Brassicaceae
Plant External Links:
NCBI TaxonomyDB:
3712
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Brazil; Turkey; Israel; Indonesia; Italy; Finland; Lebanon; United States; Jordan; SpainTraditional Medicine System:
Medicinal Functions:
Anthelmintic; Cardiotonic; Diuretic; Laxative; Stomachic
Geographical Distribution:
Brazil; Turkey; Israel; Indonesia; Italy; Finland; Lebanon; United States; Jordan; Spain
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| OPRD1; | |
| GPR35; | |
| RECQL; TDP1; MIF; HPGD; AKR1B1; HSD17B10; APEX1; POLB; | |
| TEK; MET; KDR; EGFR; NUAK1; INSR; SRC; IGF1R; FYN; CSNK2A1; | |
| CA2; CA9; CA6; | |
| SLC22A6; | |
| SMAD3; HSPA1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | MIF | Macrophage migration inhibitory factor | P14174 | CHEMBL2085 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 3.307E-11 | 3.027E-07 | EGFR, FYN, IGF1R, INSR, KDR, SRC |
| MF | GO:0060089; molecular transducer activity | GO:0004714; transmembrane receptor protein tyrosine kinase activity | 1.868E-10 | 3.698E-07 | EGFR, IGF1R, INSR, KDR, MET, TEK |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 4.348E-08 | 2.309E-05 | EGFR, FYN, INSR, MET, SRC, TEK |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.343E-07 | 5.518E-05 | CSNK2A1, EGFR, FYN, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, RECQL, SRC, TEK |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.809E-07 | 6.877E-05 | EGFR, INSR, KDR |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.534E-07 | 8.901E-05 | APEX1, CA2, CA9, CSNK2A1, EGFR, HPGD, SLC22A6, SRC, TEK |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.745E-07 | 2.497E-04 | CA2, CA6, CA9 |
| BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 1.653E-06 | 3.712E-04 | CA2, CA9, EGFR, MET, SMAD3, SRC |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.742E-06 | 3.756E-04 | APEX1, POLB |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 5.796E-06 | 1.026E-03 | EGFR, KDR, MIF, SRC, TEK |
| MF | Unclassified; | GO:0032403; protein complex binding | 6.416E-06 | 1.118E-03 | APEX1, EGFR, FYN, IGF1R, INSR, KDR, SMAD3, SRC |
| BP | Unclassified; | GO:0006461; protein complex assembly | 7.488E-06 | 1.274E-03 | HSD17B10, HSPA1A, IGF1R, INSR, MIF, SLC22A6, SMAD3, SRC, TEK |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 7.729E-06 | 1.295E-03 | FYN, IGF1R, INSR |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.257E-05 | 1.837E-03 | AKR1B1, APEX1, EGFR, SRC |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.501E-05 | 2.122E-03 | CA2, CA6, CA9 |
| BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 1.905E-05 | 2.593E-03 | AKR1B1, APEX1, KDR, OPRD1 |
| BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 2.231E-05 | 2.971E-03 | EGFR, INSR, SMAD3 |
| BP | GO:0051179; localization | GO:1900182; positive regulation of protein localization to nucleus | 2.611E-05 | 3.364E-03 | EGFR, FYN, SMAD3, SRC |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.682E-05 | 3.421E-03 | CSNK2A1, EGFR, FYN, HPGD, IGF1R, KDR, MET, MIF, SLC22A6, SMAD3 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.764E-05 | 3.449E-03 | CA2, CA6, CA9 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 3.275E-05 | 3.813E-03 | AKR1B1, APEX1, EGFR, KDR, SRC |
| BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 3.644E-05 | 4.176E-03 | EGFR, POLB |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 5.422E-05 | 5.787E-03 | EGFR, IGF1R, INSR |
| BP | GO:0050896; response to stimulus | GO:0071375; cellular response to peptide hormone stimulus | 6.171E-05 | 6.492E-03 | APEX1, FYN, INSR, SRC |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 9.365E-05 | 9.185E-03 | FYN, KDR, TEK |
| MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 9.365E-05 | 9.185E-03 | EGFR, FYN, MET |
| MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 9.511E-05 | 9.205E-03 | IGF1R, INSR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 3.522E-14 | 3.980E-12 | SMAD3, CSNK2A1, SRC, INSR, FYN, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 7.306E-09 | 4.128E-07 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 3.003E-08 | 1.131E-06 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.917E-07 | 5.416E-06 | SRC, KDR, FYN, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 3.810E-07 | 8.611E-06 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 4.058E-06 | 6.551E-05 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 5.671E-06 | 8.010E-05 | SRC, KDR, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 9.090E-06 | 1.141E-04 | INSR, TEK, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 2.494E-05 | 2.819E-04 | SMAD3, INSR, EGFR, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 7.709E-05 | 7.919E-04 | INSR, HSPA1A, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 9.241E-05 | 8.702E-04 | SRC, MET, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.051E-04 | 9.137E-04 | MET, EGFR, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.310E-06 | 2.468E-05 | CA2, CA6, CA9 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 2.816E-04 | 2.273E-03 | SRC, EGFR, HSPA1A |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 7.131E-04 | 5.372E-03 | CSNK2A1, FYN, HSPA1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 8.417E-04 | 5.595E-03 | INSR, FYN, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.617E-03 | 8.704E-03 | SMAD3, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.601E-03 | 8.704E-03 | HPGD, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.292E-03 | 7.682E-03 | SRC, EGFR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.916E-03 | 9.840E-03 | INSR, IGF1R |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05020 | Prion diseases | 9.417E-04 | 5.912E-03 | FYN, HSPA1A |
| 09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 8.370E-04 | 5.595E-03 | POLB, APEX1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MIF; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Breast cancer | C50 | IGF1R; KDR; INSR; EGFR; CA9; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | OPRD1; AKR1B1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MET; IGF1R; KDR; CSNK2A1; TEK; EGFR; SRC; CA9; |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; IGF1R; KDR; TEK; EGFR; SRC; CA9; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Prostate cancer | C61 | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; EGFR; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Refractory autoimmune diseases | D84.9, M35.9 | MIF; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; EGFR; |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR; |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRD1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | IGF1R; INSR; OPRD1; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
| C00-D49: Neoplasms | AML | NA | KDR; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; SRC; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | OPRD1; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | MIF; INSR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; CA9; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
